NCT05886374View on ClinicalTrials.gov

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

HMPL-415S1

HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

Hutchmed
All Listed Sponsors
lead

Hutchmed

INDUSTRY

NCT05886374 - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter